A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are historically a targeted oncology company focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. In May 2024, after an in-depth assessment of the value proposition of our programs for both patients and company stakeholders, we announced our intention to seek strategic alternatives for the business in an effort to maximize value for shareholders. At that time, we discontinued development of IK-930, our selective Hippo pathway inhibitor. While dedicating our efforts towards this corporate strategy, we allocated resources to continue the development of our RAS pathways program, IK-595. IK-595 is a molecular glue designed to trap MEK and RAF in an inactive complex to more completely inhibit RAS signals than existing inhibitors.
| Metric | TTM | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 0 | - | - | 31M | - |
| Net Income | -48M | -68M | -69M | -34M | -44M |
| EPS | $-12.26 | $-19.56 | $-22.80 | $-14.64 | $-192.00 |
| Free Cash Flow | 0 | -80M | -76M | -62M | -39M |
| ROIC | -25.8% | -39.9% | -46.8% | -16.4% | -20.9% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.01 | 0.17 | 0.19 | -0.63 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -52M | -75M | -71M | -34M | -45M |
| Operating Margin | 0.0% | - | - | -110.2% | - |
| ROE | -34.0% | -40.2% | -46.8% | -16.4% | - |
| Shares Outstanding | 11M | 3M | 3M | 2M | 3M |
| Metric | 2020 | 2021 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | N/A | 31M | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -45M | -34M | -71M | -75M | -52M |
| Op. Margin | N/A | -110.2% | N/A | N/A | 0.0% |
| Net Income | -44M | -34M | -69M | -68M | -48M |
| Net Margin | N/A | -110.1% | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||
| ROIC | -20.9% | -16.4% | -46.8% | -39.9% | -25.8% |
| ROE | N/A | -16.4% | -46.8% | -40.2% | -34.0% |
| ROA | -26.3% | -13.8% | -39.9% | -35.5% | -29.6% |
| Cash Flow | |||||
| Op. Cash Flow | -38M | -60M | -74M | -80M | -47M |
| Free Cash Flow | -39M | -62M | -76M | -80M | 0 |
| Owner Earnings | -40M | -66M | -82M | -88M | -56M |
| CapEx | 766K | 1.8M | 1.4M | 414K | 0 |
| Maint. CapEx | 300K | 544K | 751K | 1.0M | 1.0M |
| Growth CapEx | 466K | 1.2M | 680K | 0 | 0 |
| D&A | 300K | 544K | 751K | 1.0M | 1.0M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 663K | 663K |
| Buyback Yield | N/A | N/A | N/A | 0.8% | 1.0% |
| Stock-Based Comp | 1.8M | 5.2M | 7.5M | 7.6M | 7.6M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | N/A | N/A | N/A | -175M | -143M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | 143M |
| Long-Term Debt | N/A | N/A | N/A | 950K | 950K |
| Debt/Equity | -0.63 | 0.19 | 0.17 | 0.01 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A |
| Equity | -101M | 208M | 147M | 170M | 140M |
| Total Assets | 168M | 248M | 172M | 192M | 161M |
| Total Liabilities | 63M | 40M | 25M | 22M | 6.9M |
| Intangibles | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -111M | -145M | -214M | -282M | -282M |
| Working Capital | 138M | 209M | 139M | 164M | 164M |
| Current Assets | 166M | 237M | 160M | 179M | 179M |
| Current Liabilities | 28M | 27M | 22M | 14M | 14M |
| Per Share Data | |||||
| EPS | -192.00 | -14.64 | -22.80 | -19.56 | -12.26 |
| Owner EPS | -13.27 | -28.31 | -27.32 | -25.36 | -4.97 |
| Book Value | -33.58 | 89.21 | 48.73 | 48.71 | 12.51 |
| Cash Flow/Share | -12.57 | -25.86 | -24.57 | -22.88 | -4.16 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 3.0M | 2.3M | 3.0M | 3.5M | 11.2M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -0.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 1.8 | 0.7 | 0.5 | 0.5 |
| Price/Sales | N/A | 13.5 | N/A | N/A | N/A |
| FCF Yield | N/A | -16.6% | -74.5% | -94.9% | N/A |
| Market Cap | N/A | 373M | 101M | 84M | 64M |
| Avg. Price | N/A | 179.53 | 64.42 | 52.45 | 5.73 |
| Year-End Price | N/A | 160.20 | 33.60 | 24.24 | 5.73 |
ImageneBio, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Total shareholder yield (buybacks) is 1.0%.
ImageneBio, Inc. (IMA) has a 5-year average return on invested capital (ROIC) of -31.0%. This is below average and may indicate limited pricing power.
ImageneBio, Inc. (IMA) has a market capitalization of $64M. It is classified as a small-cap stock.
ImageneBio, Inc. (IMA) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 1.03%.
ImageneBio, Inc. (IMA) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
ImageneBio, Inc. (IMA) generated $-80 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
ImageneBio, Inc. (IMA) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
ImageneBio, Inc. (IMA) reported earnings per share (EPS) of $-19.56 in its most recent fiscal year.
ImageneBio, Inc. (IMA) has a return on equity (ROE) of -40.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for ImageneBio, Inc. (IMA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ImageneBio, Inc. (IMA) has a book value per share of $48.71, based on its most recent annual SEC filing.